Gane E. Safety and Efficacy at 1 year after Switching from Tenofovir Disoproxil Fumurate to Tenofovir Alafenamide in Chronic HBV Patients with Risk Factors for TDF Use. PS-156.
Promotie: Mechanismen achter antistofgemedieerde ontsteking
feb 2021 | Bacteriële infecties, Virale infecties